Minerva Neurosciences (NASDAQ:NERV) Stock Passes Below 200 Day Moving Average – Time to Sell?

Minerva Neurosciences, Inc. (NASDAQ:NERV) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.80 and traded as low as $2.44. Minerva Neurosciences shares last traded at $2.46, with a volume of 42,326 shares.

Analysts Set New Price Targets

A number of brokerages recently weighed in on NERV. StockNews.com started coverage on Minerva Neurosciences in a research note on Friday. They issued a “sell” rating on the stock. HC Wainwright decreased their price objective on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th.

Minerva Neurosciences Stock Performance

The stock has a market cap of $17.05 million, a P/E ratio of -0.55 and a beta of 0.14. The firm has a 50 day moving average of $2.68 and a two-hundred day moving average of $2.80.

Minerva Neurosciences (NASDAQ:NERV) last announced its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, sell-side analysts anticipate that Minerva Neurosciences, Inc. will post -2.26 EPS for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.